Rockwell Sees Opportunity For Triferic In Cost-Sensitive CKD Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Rockwell Medical has filed an NDA for the iron replacement therapy, which will be positioned as an alternative to I.V. iron during dialysis and could limit the need for erythropoietin-stimulating agents.